Navigation Links
AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
Date:8/11/2009

harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are required by a governmental authority or applicable law.

Attachment: Financial summary

    Quarterly Interim Consolidated Statements of Loss (unaudited)

                                  Three months ended        Six months ended
                                        June 30,                June 30,
    (in thousands)                  2009        2008        2009        2008
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
                                       $           $           $           $
    Revenues
    Sales and royalties            5,427       8,250      10,398      16,192
    License fees and
'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... Riordan-McKenna Institute ... announced today that the use of sterile, dehydrated amniotic tissue AlphaPATCH™ developed by ... otherwise non-healing surgical knee wound. , The case involved a 78-year-old male, who ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... venture capital funds, investment firms and animal health companies to hear from animal ... $160 million. Several have also received licensing agreements or distribution contracts. This ...
(Date:8/27/2015)... 27, 2015  Neogen Corporation (NASDAQ: NEOG ) ... United Kingdom -based Lab M Holdings, ... and diagnostic systems. Lab M was ... provider of microbial testing and diagnostic products for the ... company currently sells into more than 70 countries worldwide, ...
(Date:8/27/2015)... -- The National Necrotizing Fasciitis Foundation (NNFF) ... doctors at Vanderbilt University Hospital in Nashville, ... Dr. John Crew , director of the ... in Daly City, CA. ... by Dr. Crew, that had previously saved the lives ...
Breaking Biology Technology:Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Neogen acquires U.K.-based Lab M Holdings 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3
... SAN DIEGO, Oct. 16 CardioDynamics (Nasdaq:,CDIC), ... technology,has been named to Deloitte,s prestigious Technology Fast ... 50 fastest growing technology, media,telecommunications, and life sciences ... LLP, one of the nation,s leading professional services,organizations. ...
... Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) today ... presentations at the AACR-NCI-EORTC,International Conference on Molecular Targets ... They will highlight drug discovery,efforts focused on significant ... like kinase 1 (PLK1) and Janus tyrosine kinase,2 ...
... Stockholder Meeting October 23, IRVINE, California, October ... an orthobiologics company, today announced the,interim tabulation results ... 2007 and adjourned to October 23, 2007. ... 36 percent,of the shares entitled to vote, voted ...
Cached Biology Technology:CardioDynamics Ranked in Deloitte's Technology Fast 50 Program for San Diego 2CardioDynamics Ranked in Deloitte's Technology Fast 50 Program for San Diego 3CardioDynamics Ranked in Deloitte's Technology Fast 50 Program for San Diego 4Rigel to Present Research Programs at Scientific Conferences 2Rigel to Present Research Programs at Scientific Conferences 3IsoTis Reports Interim Results of Vote for Integra Merger 2IsoTis Reports Interim Results of Vote for Integra Merger 3IsoTis Reports Interim Results of Vote for Integra Merger 4
(Date:8/4/2015)... ) today reported financial and operating results for the second quarter ... quarter contract revenue of $ 85.2 million, a ... of 26 % , Second quarter adjusted ... royalties in the current quarter , Operating cash ... to present another strong financial quarter, with all our divisions achieving ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 ... sobre Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 ... . La conferencia celebra su décimo ... se ha convertido en una de las reuniones anuales ... ,ómicas, y es una de las conferencias científicas más ...
(Date:7/31/2015)... de julio de 2015 La 10 th ... por medio de BGI del 22 al 25 de octubre de ... Este año, la conferencia celebra su décimo aniversario. Desde ... en una de las reuniones anuales más influyentes del mundo ... reuniones más dinámicas, entusiastas y mejores a nivel científico. ...
Breaking Biology News(10 mins):AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... A Duke University study suggests that evolution can behave ... depend on an energy-efficient style of four-footed running over ... have evolved a profoundly inefficient gait, tailor-made to creep ... "It is usually assumed that efficiency is what ...
... Using a harmless virus to insert a corrective gene ... Research Hospital have alleviated sickle cell disease pathology. In ... showed essentially no difference from normal mice. Although the ... presents significant technical obstacles, they believe that the new ...
... failing to take their medication for a range of ... a new university research project. The 21-month study ... The University of Leicester will draw on the experiences ... and epilepsy to learn about the barriers that prevent ...
Cached Biology News:Dogs chase efficiently, but cats skulk counterintuitively 2Gene therapy corrects sickle cell disease in laboratory study 2Gene therapy corrects sickle cell disease in laboratory study 3A spoonful of sugar? 2A spoonful of sugar? 3
... The OneSTrEP Protein Interaction Kit provides ... step method to isolate intact protein ... tedious optimization or multiple purification steps, ... highly selective StrepTactin Superflow Column for ...
Request Info...
... The system consists ... (Cat. No. 17001-082) and ... 17002-080). It is complete ... promoting agents, and requires ...
... The product contains 5 ml Dynabeads Tosylactivated ... p-toluenesulphonyl (tosyl) reactive groups. For coupling of ... hydrophobically on initial coupling with covalent binding ... and sulphydryll groups (SH)) occurringovernight. Coupling reactions ...
Biology Products: